drugset / Trial / NCT01245790

A Study of Fostamatinib in Subjects With Impaired Kidney Function

NCT01245790

Phase 1 Completed 24 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelBasic science

Summary

A 2 stage study to evaluate the amount of fostamatinib in the blood and urine in subjects with impaired kidney (renal) function compared with healthy volunteers with normal renal function. Stage 1 will include healthy subjects and subjects with end stage renal disease, while Stage, 2 may include subjects with mild, moderate and/or severe renal impairment dependent on the outcome of Stage 1. The study will also evaluate safety and tolerability in subjects with renal impairment.

Timeline

Start
2010-11
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fostamatinib Small molecule 150 mg Oral